A Double-Blind, Randomized, Placebo-Controlled Phase 2b Study of 100, 200, and 300 mg BID Dextofisopam in Female Outpatients With Irritable Bowel Syndrome.

Trial Profile

A Double-Blind, Randomized, Placebo-Controlled Phase 2b Study of 100, 200, and 300 mg BID Dextofisopam in Female Outpatients With Irritable Bowel Syndrome.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Aug 2011

At a glance

  • Drugs Dextofisopam (Primary)
  • Indications Irritable bowel syndrome
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Sep 2009 Results have been reported by Pharmos Corporation in a media release.
    • 14 Sep 2009 Primary endpoint, % of weeks responding for adequate overall relief of irritable bowel syndrome symptoms has not been met.
    • 01 Sep 2009 Actual patient number (324) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top